Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from KDventures AB ( ($SE:KDV.B) ).
KDventures AB, the Stockholm-listed life science investment company, has decided to fully exercise its allocation in Modus Therapeutics’ TO2 warrant program, investing approximately SEK 5.1 million at a subscription price of SEK 0.35 per share. The move reinforces KDventures’ already dominant stake in Modus Therapeutics, where it holds 56 percent directly and 2 percent indirectly, and supports the portfolio company’s financing as the full warrant program is expected to raise about SEK 10 million before transaction costs.
By participating in full, KDventures signals continued confidence in Modus Therapeutics’ prospects and underlines its strategy of actively supporting portfolio companies through key funding windows. The additional capital injection into Modus, which is listed on Nasdaq First North Growth Market, may strengthen the biotech firm’s financial position and development plans, while consolidating KDventures’ influence over its operational and strategic direction.
More about KDventures AB
KDventures AB is a Nordic investment company focused on the life sciences sector, listed on Nasdaq Stockholm under the ticker KDV. It identifies and backs innovative pharmaceutical projects and medical technology products originating from leading Nordic research institutions, giving investors exposure to both listed and private life science assets with substantial growth potential.
Average Trading Volume: 1,499,446
Technical Sentiment Signal: Sell
Current Market Cap: SEK169.3M
See more insights into KDV.B stock on TipRanks’ Stock Analysis page.